STOCK TITAN

Cresco Labs Closes New Senior Secured Credit Facility with Existing Lenders

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Cresco Labs (CSE:CL) (OTCQX:CRLBF) announced the closure of an agreement to upsize its senior secured term loan to US$400 million, with a reduced interest rate of 9.5% per annum and a maturity date of August 12, 2026. The funds will be used to retire a US$200 million credit facility, finance capital expenditures, and support growth initiatives in the U.S. cannabis sector. This move is seen as a strategy to improve capital structure and flexibility without diluting shareholder equity.

Positive
  • Increased senior secured term loan to US$400 million.
  • Reduced interest rate to 9.5%, improving cost of capital.
  • No equity or convertible components, protecting shareholder equity.
  • Funds aimed at growth initiatives in the U.S. cannabis sector.
Negative
  • None.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the closing of an agreement with lenders to upsize its senior secured term loan (the “Senior Loan”) to an aggregate principal amount of US$400 million. The Senior Loan bears interest at a reduced rate of 9.5% per annum, with a maturity date of August 12, 2026.

The Company intends to use the proceeds from the Senior Loan to retire its existing US$200 million credit facility, fund capital expenditures, and pursue other targeted growth initiatives within the U.S. cannabis sector. The Senior Loan does not include any equity or convertible components and the total facility amount is being provided by a syndicate of five existing, institutional lenders.

“Today we have secured funding to capitalize on new growth opportunities, improved our cost of capital without diluting shareholders, simplified our capital structure, and given ourselves enhanced flexibility in a dynamic capital environment.” said Charlie Bachtell, CEO of Cresco Labs. “This agreement to extend and increase our Senior Loan reflects the unique value proposition that Cresco Labs has demonstrated and the confidence our investors have in our differentiated strategy.”

The terms of the Senior Loan were negotiated at arm's length with the agent and lead investor and include customary restrictive covenants.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

FAQ

What is the recent loan agreement for Cresco Labs (CRLBF)?

Cresco Labs announced the closing of an agreement to upsize its senior secured term loan to US$400 million.

What are the interest rates on Cresco Labs' new loan?

The new senior secured term loan has a reduced interest rate of 9.5% per annum.

What is the maturity date for Cresco Labs' term loan?

The maturity date for the term loan is August 12, 2026.

How will Cresco Labs use the proceeds from the loan?

The proceeds will retire an existing US$200 million credit facility, fund capital expenditures, and support growth in the cannabis sector.

Does the new loan agreement dilute Cresco Labs' shareholders?

No, the loan does not include any equity or convertible components, thus protecting shareholder equity.

CRESCO LABS INC

OTC:CRLBF

CRLBF Rankings

CRLBF Latest News

CRLBF Stock Data

374.59M
271.34M
0.66%
5.5%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Chicago